RE: Integrity6 Apr 2020 21:29
Hi all,
New to the bb boards, been following this since jumping over a week.
Trinityman is absolutely right. One thing to bear in mind is these trials are DOUBLE-BLIND. Neither the patient nor the clinician/respiratory nurse know whether they are administering the treatment or the placebo.
The only information a nurse could provide is how many patients have been recruited to the trial and how many have been released. (I know this could still be valuable but I reckon certain respiratory nurses have been given a word.)
FWIW - I absolutely think this treatment is a runner. With COVID-19, Synairgen have the opportunity to finally dot the i's and cross the t's on this treatment.
Also, apologies if this has been covered, but where do the licensing rights sit for SNG001? Googling SNG001 AstraZeneca - top link shows an article from AZ themselves in 2014 where AZ have a "global licence agreement ... for SNG001"